Granted Patent
B2
US 12,203,933 · App. 17/254,086 · Granted Jan 21, 2025
Methods and materials for identifying and treating membranous nephropathy
Inventors:
M. Cristine Charlesworth (Rochester, MN); Sanjeev Sethi (Rochester, MN); Fernando C. Fervenza (Rochester, MN); Benjamin J. Madden (Stewartville, MN)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and/or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and/or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.
Claims (17)
1. A method for treating a mammal having membranous nephropathy, wherein said method comprises administering an immunosuppressant to a mammal identified as having (i) autoantibodies specific for a polypeptide or (ii) kidney tissue comprising an elevated level of said polypeptide as compared to a level of said polypeptide in normal kidney tissue, wherein said polypeptide is an exostosin 1 (EXT1) polypeptide or an exostosin 2 (EXT2) polypeptide.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein said mammal was identified as having said autoantibodies.
4. The method of claim 1 , wherein said mammal was identified as having said kidney tissue.
5. The method of claim 1 , wherein said polypeptide is said EXT1 polypeptide.
6. The method of claim 1 , wherein said polypeptide is said EXT2 polypeptide.
7. The method of claim 1 , wherein the level of autoantibodies present within said mammal is reduced by at least 5 percent following said administering step.
8. The method of claim 1 , wherein the level of autoantibodies present within said mammal is reduced by at least 25 percent following said administering step.
9. The method of claim 1 , wherein the level of autoantibodies present within said mammal is reduced by at least 50 percent following said administering step.
10. The method of claim 1 , wherein said immunosuppressant is a B-cell inhibitor.
11. The method of claim 10 , wherein said B-cell inhibitor is rituximab.
12. The method of claim 1 , wherein said immunosuppressant is a calcineurin inhibitor.
13. The method of claim 12 , wherein said calcineurin inhibitor is cyclosporine or tacrolimus.
14. The method of claim 1 , wherein said immunosuppressant is an mTOR inhibitor.
15. The method of claim 14 , wherein said mTOR inhibitor is sirolimus or everolimus.
16. The method of claim 1 , wherein said immunosuppressant is a DNA damage inducer.
17. The method of claim 16 , wherein said DNA damage inducer is chlorambucil.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2021
From: CHARLESWORTH, M. CRISTINE; SETHI, SANJEEV; FERVENZA, FERNANDO C.; MADDEN, BENJAMIN J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 055054/0715 →
Continuity (2)
Provisional Application
62764681
· Aug 15, 2018
References Cited (164)
US 8361721B2
· Copland et al.
· 2013
[cited by applicant]
US 20060040293A1
· Salonen et al.
· 2006
[cited by applicant]
US 20100167285A1
· Schreiber et al.
· 2010
[cited by applicant]
US 20100196426A1
· Skog et al.
· 2010
[cited by applicant]
US 20130280738A1
· Salant et al.
· 2013
[cited by applicant]
US 20130303395A1
· Lueking et al.
· 2013
[cited by applicant]
US 20170216244A1
· Tufro
· 2017
[cited by applicant]
US 20230314425A1
· Sethi et al.
· 2023
[cited by applicant]
EP 2977758
· 2016
[cited by applicant]
WO WO2008118969
· 2008
[cited by applicant]
WO WO2016012542
· 2016
[cited by applicant]
WO WO2017009245
· 2017
[cited by applicant]
WO WO2018031947
· 2018
[cited by applicant]
WO WO2019030461
· 2019
[cited by applicant]
WO WO2020037135
· 2020
[cited by applicant]
WO WO2021178863
· 2021
[cited by applicant]
WO WO2022103598
· 2022
[cited by applicant]
WO WO2023172847
· 2023
[cited by applicant]
Karp et al., Genetics of Childhood Steroid Sensitive Nephrotic Syndrome (SSNS), Pediatr. Nephrol., 32(9), (2017), p. 1481-1488 (Year: 2017).
[cited by examiner]
MedlinePlus. “EXT1 gene”. https://medlineplus.gov/genetics/gene/ext1/. (2017). Accessed: May 17, 2024 (Year: 2017).
[cited by examiner]
Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Detection of Nucleic Acids and Proteins. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9916/ (Year: 2000).
[cited by examiner]
Bech et al., “Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy,” Clin. J. Am. Soc. Nephrology, Aug. 7, 2014, 9(8):1386-1392.
[cited by applicant]
EP Extended Search Report in European Appln. No. 19850371.6, dated Feb. 2, 2022, 11 pages.
[cited by applicant]
Iwakura et al., “Primary Membranous Nephropathy with Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases,” Kidney Medicine, May 31, 2021, 3(4):669-673.
[cited by applicant]
Bobart et al., “A Target Antigen-Based Approach to the Classification of Membranous Nephropathy,” Mayo Clin. Proceedings, Mar. 2021, 96(3):577-591.
[cited by applicant]
Du et al., “Elevated semaphorin5A in systemie lupus erythematosus is in association with disease activity and lupus nephritis,” Clin. Exp. Immunology, Feb. 17, 2017, 188(2):234-242.
[cited by applicant]
Ahn et al., “Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1),” Nat. Genetics, Oct. 1, 1995, 11(2):137-143.
[cited by applicant]
Alarcón, “Multiethnic lupus cohorts: what have they taught US?,” Reumatol. Clinica, Dec. 23, 2010, 7(1):3-6.
[cited by applicant]
Almaani et al., “Update on Lupus Nephritis,” Clin. J. Am. Soc. Nephrology, Nov. 7, 2016, 12(5):825-835.
[cited by applicant]
Alto et al., “Semaphorins and their Signaling Mechanisms,” Methods Mol. Biology, Oct. 28, 2016, 1493:1-25.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search. programs,” Nucleic Acids Research, Sep. 1, 1997, 25(17):3389-3402.
[cited by applicant]
Anders, “Nephropathic autoantigens in the spectrum of lupus nephritis,” Nat. Rev. Nephrology, Jun. 13, 2019, 15(10):595-596.
[cited by applicant]
Aoki et al., “The reduction of heparan sulphate in the glomerular basement membrane does not augment urinary albumin excretion,” Nephrol. Dial. Transplantation, Jan. 1, 2018, 33(1):26-33.
[cited by applicant]
Bajema et al., “Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chron…
[cited by applicant]
Beck Jr. et al., “Membranous nephropathy: from models to man,” J. Clin. Investigation, Jun. 2, 2014, 124(6):2307-2314.
[cited by applicant]
Beck Jr. et al., “M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” N. Engl. J. Medicine, Jul. 2, 2009, 361(1):11-21.
[cited by applicant]
Beck Jr. et al., “Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy,” J. Am. Soc. Nephrology, Jul. 22, 2011, 22(8):1543-1550.
[cited by applicant]
Bertelli et al., “Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease,” Front. Medicine, Jun. 11, 2018, 5:170, 13 pages.
[cited by applicant]
Borza, “Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation,” Matrix Biology, Sep. 6, 2016, 57-58:299-310.
[cited by applicant]
Brasch et al., “Thinking outside the cell: how cadherins drive adhesion,” Trends Cell Biology, May 1, 2012, 22(6):299-310.
[cited by applicant]
Busse et al., “Contribution of EXT1, EXT2, and EXTL3 to Heparan Sulfate Chain Elongation,” J. Biol, Chemistry, Nov. 9, 2007, 282(45):32802-32810.
[cited by applicant]
Busse et al., “In Vitro Polymerization of Heparan Sulfate Backbone by the EXT Proteins,” J. Biol. Chemistry, Oct. 17, 2003, 278(42):41333-41337.
[cited by applicant]
Busse-Wicher et al., “The extostosin family: Proteins with many functions,” Matrix Biology, Apr. 2014, 35:25-33.
[cited by applicant]
Chen et al., “Glomerular basement membrane and related glomerular disease,” Transl. Research, Oct. 2012, 160(4):291-297.
[cited by applicant]
Chen et al., “Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria,” Kidney International, Aug. 2008, 74(3):289-299.
[cited by applicant]
Chen et al., “Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices,” Kidney International, Dec. 1, 2010, 78(11):1088-1099.
[cited by applicant]
Cook et al., “Genetic Heterogeneity in Families with Hereditary Multiple Exostoses,” Am. J. Hum. Genetics, Jul. 1993, 53(1):71-79.
[cited by applicant]
Couser, “Primary Membranous Nephropathy,” Clin. J. Am. Soc. Nephrology, May 26, 2017, 12(6):983-997.
[cited by applicant]
De Vriese et al., “A Proposal for a Serology-Based Approach to Membranous Nephropathy,” J. Am. Soc. Nephrology, Oct. 24, 2016, 28(2):421-430.
[cited by applicant]
Duncan et al., “The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins,” J. Clin. Investigation, Aug. 2001, 108(4):511-516.
[cited by applicant]
Fervenza et al., “Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.” N. Engl. J. Medicine, Jul. 4, 2019, 381(1):36-46.
[cited by applicant]
Frank et al., “Protocadherins,” Curr. Opin, Cell Biology, Oct. 2002, 14(5):557-562.
[cited by applicant]
Guan et al., “Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival,” Kidney International, May 2006, 69(9):1564-1569.
[cited by applicant]
Halbleib et al., “Cadherins in development: cell adhesion, sorting, and tissue morphogenesis,” Genes Development, Dec. 1, 2006, 20(23):3199-3214.
[cited by applicant]
Hanset et al., “Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study,” Am. J. Kidney Diseases, Jul. 12, 2020, 76(5):624-635.
[cited by applicant]
Hasebe et al., “Efficient Production and Characterization of Recombinant Human NELLI Protein in Human Embryonic Kidney 293-F Cells,” Mol. Biotechnology, Aug. 5, 2011, 51(1):58-66.
[cited by applicant]
Hasebe et al., “The C-terminal region of NELLI mediates osteoblastic cell adhesion through integrin α3β1,” FEBS Letters, Jun. 20, 2012, 586(16):2500-2506.
[cited by applicant]
Herwig et al., “Thrombospondin Type I Domain-Containing 7A Localizes to the Slit Diaphragm and Stabilizes Membrane Dynamics of Fully Differentiated Podocytes,” J. Am. Soc. Nephrology, Apr. 10, 2019, 30(5):824-839.
[cited by applicant]
Hihara et al., “Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy,” PLoS One, Jun. 29, 2016, 11(6):e0158154, 12 pages.
[cited by applicant]
Huong et al., “Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center,” Medicine (Baltimore), May 1999, 78(3):148-166.
[cited by applicant]
Itakura et al., “Heparan sulfate is a clearance receptor for aberrant extracellular proteins,” J. Cell Biology, Mar. 2, 2020, 19(3):e201911126.
[cited by applicant]
Kanwar et al., “Contribution of Proteoglycans Towards the Integrated Functions of Renal Glomerular Capillaries: A Historical Perspective,” Am. J. Pathology, Jul. 2007, 171(1):9-13.
[cited by applicant]
Kuroda et al., “Biochemical Characterization and Expression Analysis of Neural Thrombospondin-1-like Proteins NELLI and NELL2,” Biochem. Biophys. Res. Communications, Nov. 1999, 265(1):79-86.
[cited by applicant]
Lee et al., “Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis,” Lupus, Jan. 24, 2016, 25(7):727-734.
[cited by applicant]
Luce et al., “The neuronal EGF-related genes NELLI and NELL2 are expressed in hemopoietic cells and developmentally regulated in the B lineage,” Gene, Apr. 29, 1999, 231(1-2):121-126.
[cited by applicant]
Makker et al., “Idiopathic membranous nephropathy: an autoimmune disease,” Semin. Nephrology, Jul. 2011, 31(4):333-340.
[cited by applicant]
Matshuhashi et al., “New gene, nel, encoding a M(r) 93 K protein with EGF-like repeats is strongly expressed in neural tissues of early stage chick embryos,” Dev. Dynamics, Jun. 1995, 203(2):212-222.
[cited by applicant]
McCarthy et al., “The Glomerular Basement Membrane as a Model System to Study the Bioactivity of Heparan Sulfate Glycosaminoglycans,” Microsc. Microanalysis, Feb. 2012, 18(1):3-21.
[cited by applicant]
McCormick et al., “The putative tumor suppressors EXTI and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate,” Proc. Natl. Acad. Sci. USA, Jan. 18, 2000, 9…
[cited by applicant]
Miner, “Glomerular basement membrane composition and the filtration barrier,” Pediatr. Nephrology, Feb. 15, 2011, 26(9):1413-1417.
[cited by applicant]
Miner, “Glomerular filtration: the charge debate charges ahead,” Kidney International, Aug. 2008, 74(3):259-261.
[cited by applicant]
Miner, “The glomerular basement membrane,” Exp. Cell Research, Mar. 5, 2012, 318(9):973-978.
[cited by applicant]
Morishita et al., “Protocadherin family: diversity, structure, and function,” Curr. Opin. Cell Biology, Oct. 23, 2007, 19(5):584-592.
[cited by applicant]
Nakamura et al., “Expression and regulatory effects on cancer cell behavior of NELLI and NELL2 in human renal cell carcinoma,” Cancer Science, Mar. 26, 2015, 106(5):656-664.
[cited by applicant]
Nesvizhskii et al., “A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry,” Anal. Chemistry, Jul. 15, 2003, 75(17):4646-4658.
[cited by applicant]
Neufeld et al., “The semaphorins and their receptors as modulators of tumor progression,” Drug Resist. Updates, Aug. 28, 2016, 29:1-12.
[cited by applicant]
Paulson et al., “Glycosyltransferases: Structure, localization, and control of cell type-specific glycosylation,” J. Biol. Chemistry, Oct. 15, 1989, 264(3):17615-17618.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appin. No. PCT/US2019/046676, dated Feb. 16, 2021, 7 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2019/046676, dated Oct. 24, 2019, 11 pages.
[cited by applicant]
Pourcine et al., “Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years,” PLoS On…
[cited by applicant]
Pozdzik et al., “Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management,” BioMed Res. International, Jan. 8, 2018, 2018:6281054, 19 pages.
[cited by applicant]
ProteinAtlas.org [online], “NELLI - Kidney,” available on or before Feb. 9, 2021 via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20210209071800/https://www.proteinatlas.org/ENSG00000165973-NELL1/ti…
[cited by applicant]
ProteinAtlas.org [online], “PCDH7—Kidney,” available on or before Jun. 26, 2015 via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20150626215650/https://www.proteinatlas.org/ENSG00000169851-PCDH7/tis…
[cited by applicant]
Raats et al., “Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuria,” Kidney International, Feb. 2000, 57(2):385-400.
[cited by applicant]
Ravindran et al., “In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes,” J. Am. Soc. Nephrology, Jan. 21, 2021, 32(3):695-706.
[cited by applicant]
Ravindran et al., “Proteomic Analysis of Complement Proteins in Membranous Nephropathy,” Kidney Int. Reports, Jan. 30, 2020, 5(5):618-626.
[cited by applicant]
Roberts et al., “Familial Nephropathy and Multiple Exostoses With Exostosin-1 (EXT1) Gene Mutation,” J. Am. Soc. Nephrology, Mar. 2008, 19(3):450-453.
[cited by applicant]
Ronco et al., “Pathogenesis of membranous nephropathy: recent advances and future challenges,” Nat. Rev. Nephrology, Feb. 28, 2012, 8(4):203-213.
[cited by applicant]
Ronco et al., “Pathophysiological advances in membranous nephropathy: time for a shift in patient's care,” Lancet, May 16, 2015, 385(9981):1983-1992.
[cited by applicant]
Rops et al., “Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis,” Kidney International, Apr. 23, 2014, 86(5):932-942.
[cited by applicant]
Rosini et al., “Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites,” Sci. Signaling, May 29, 2018, 11(532):eaar2566, 16 pages.
[cited by applicant]
Sano et al., “Protocadherins: a large family of cadherin-related molecules in central nervous system,” EMBO Journal, Jun. 1993, 12(6):2249-2256.
[cited by applicant]
Sethi et al., “Exostosin I/Exostosin 2-Associated Membranous Nephropathy,” J. Am. Soc. Nephrology, May 6, 2019, 30(6):1123-1136.
[cited by applicant]
Sethi et al., “Mass Spectrometry Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis,” Clin. J. Am. Soc. Nephrology, Sep. 28, 2010, 5(12):2180-2187.
[cited by applicant]
Sethi et al., “Mass spectrometry based proteomics in the diagnosis of kidney disease,” Curr. Opin. Nephrol. Hypertension, May 2013, 22(3):273-280.
[cited by applicant]
Sethi et al., “Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy,” Kidney International, Oct. 10, 2019, 97(1):163-174.
[cited by applicant]
Sethi et al., “Protocadherin 7-Associated Membranous Nephropathy,” J. Am. Soc. Nephrology, Apr. 8, 2021, 32(5):1249-1261.
[cited by applicant]
Sethi et al., “Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients,” Kidney International, Nov. 1, 2020, 98(5):1253-1264.
[cited by applicant]
Stoddard et al., “Structure and function insights garnered from in silico modeling of the thrombospondin type-1 domain-containing 7A antigen,” Proteins, Dec. 21, 2018; 87(2):136-145.
[cited by applicant]
Stojan et al., “Epidemiology of systemic lupus erythematosus: an update,” Curr, Opin. Rheumatology, Mar. 2018, 30(2):144-150.
[cited by applicant]
Sugar et al., “N-sulfation of heparan sulfate is critical for syndecan-4-mediated podocyte cell-matrix. interactions,” Am. J. Physiol. Renal Physiology, Mar. 2, 2016, 310(1):F1123-F1135.
[cited by applicant]
Sugar et al., “Podocyte-specific deletion of NDST1, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization in vivo,” Kidney International, Aug. 7, 2013, 85(2…
[cited by applicant]
Takamatsu et al., “Diverse roles for semaphorin-plexin signaling in the immune system,” Trends Immunology, Feb. 9, 2012, 33(3):127-135.
[cited by applicant]
Tapia et al., “Semaphorin3a disrupts podocyte foot processes causing acute proteinuria,” Kidney International, Dec. 12, 2007, 73(6):733-740.
[cited by applicant]
Ting et al., “Human NELL-1 Expressed in Unilateral Coronal Synostosis,” J. Bone Miner. Research, Jan. 1999, 14(1): 80-89.
[cited by applicant]
Tomas et al., “Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy,” J. Clin. Investigation, May 23, 2016, 126(7):2519-2532.
[cited by applicant]
Tomas et al., “Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy,” N. Engl. J. Medicine, Nov. 13, 2014, 371(24):2277-2287.
[cited by applicant]
UniProt Accession No. O60245, “Protocadherin-7,” dated Jun. 7, 2017, 5 pages.
[cited by applicant]
van den Born et al., “Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases,” Kidney International, Feb. 1993, 43(2):454-463.
[cited by applicant]
Vrana et al., “Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens,” Blood, Oct. 1, 2009, 114(24):4957-4959.
[cited by applicant]
Watanabe et al., “Cloning and Characterization of Two Novel Human cDNAs (NELLI and NELL2) Encoding Proteins with Six EGF-like Repeats,” Genomics, Dec. 15, 1996, 38(3):273-276.
[cited by applicant]
Yazdani et al., “The semaphorins,” Genome Biology, Mar. 30, 2006, 7(3):211, 14 pages.
[cited by applicant]
Zaghrini et al., “Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy,” Kidney International, Mar. 2019, 95(3):666-679.
[cited by applicant]
Zhang et al., “Craniosynostosis in transgenic mice overexpressing Nell-1,” J. Clin. Investigation, Sep. 2002, 110(6):861-870.
[cited by applicant]
Zhang et al., “Overexpression of Nell-1, a Craniosynostosis-Associated Gene, Induces Apoptosis in Osteoblasts During Craniofacial Development,” J. Bone Miner. Research, Dec. 2003, 18(12):2126-2134.
[cited by applicant]
Zhang et al., “The Role of NELL-1, a Growth Factor Associated with Craniosynostosis, in Promoting Bone Regeneration,” J. Dent. Research, Jul. 20, 2010, 89(9):865-878.
[cited by applicant]
Prunotto et al., “Autoimmunity in membranous nephropathy targets aldose reductase and SOD2,” J. Am. Soc. Nephrology, Mar. 2010, 21(3):507-519.
[cited by applicant]
U.S. Appl. No. 17/642,773, filed Mar. 14, 2022, Sanjeev Sethi, Pending.
[cited by applicant]
U.S. Appl. No. 17/758,361, filed Jul. 5, 2022, Sanjeev Sethi, Pending.
[cited by applicant]
U.S. Appl. No. 18/021,641, filed Feb. 16, 2023, Sanjeev Sethi, Published as U.S. Patent Application Publication No. 2023/0314425.
[cited by applicant]
U.S. Appl. No. 18/033,903, filed Apr. 26, 2023, Fernando C. Fervenza, Pending.
[cited by applicant]
Bobart et al., “Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies,” Kidney Int., Feb. 2019, 95(2):429-438.
[cited by applicant]
Caza et al., “Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis,” Kidney Int., Jul. 2021, 100(1):171-181.
[cited by applicant]
Chang et al., “Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature,” Clin. J. Am. Soc. Nephrol., Sep. 2007, 2(5):1014-1023.
[cited by applicant]
Ciani et al., “Mice Lacking the Giant Protocadherin mFAT1 Exhibit Renal Slit Junction Abnormalities and a Partially Penetrant Cyclopia and Anophthalmia Phenotype,” Mol. Cell Biol., May 2003, 23(10):3575-3582.
[cited by applicant]
Fabretti et al., “Expanding the Spectrum of FAT1 Nephropathies by Novel Mutations That Affect Hippo Signaling, ” Kidney Int. Rep., May 2021, 6(5):1368-1378.
[cited by applicant]
Feltkamp et al., “Elution of antibodies from biopsy tissue,” J. Clin. Pathol., Oct. 1970, 23(7):629-631.
[cited by applicant]
Garred et al., “The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration,” Scand. J. Immunol., Sep. 1989, 30(3):379-382.
[cited by applicant]
Gee et al., “FAT1 mutations cause a glomerulotubular nephropathy,” Nat. Commun., Feb. 2016, 7:10822.
[cited by applicant]
Hiesse et al., “Membranous nephropathy in a bone marrow transplant recipient,” Am. J. Kidney Dis., Feb. 1988, 11(2):188-191.
[cited by applicant]
Hu, “The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular disease,” Nephrol. Dial. Transplant., Jun. 2011, 26(6):2025-2031.
[cited by applicant]
Inoue et al., “FAT is a component of glomerular slit diaphragms,” Kidney Int., Mar. 2001, 59(3):1003-1012.
[cited by applicant]
Kudose et al., “NELL1-Associated Membranous Glomerulopathy After Hematopoietic Stem Cell Transplantation,” Kidney Int. Rep., Jul. 2021, 6(7):1992-1995.
[cited by applicant]
Mahoney et al., “The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily,” Cell, Nov. 1991, 67(5):853-868.
[cited by applicant]
Michaelsen et al., “Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration,” Eu…
[cited by applicant]
Mustjoki et al., “Somatic Mutations in ‘Benign’ Disease,” N. Engl. J. Med., May 2021, 384:2039-2052.
[cited by applicant]
Na et al., “Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy,” PLoS One, Mar. 2017, 12(3):e0174501.
[cited by applicant]
Nasr et al., “Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases,” Am. J. Kidney Dis., Jun. 2022, 79(6):904-908.
[cited by applicant]
Nergizoglu et al., “Chronic graft-versus-host disease complicated by membranous glomerulonephritis,” Nephrol. Dial. Transplant., Oct. 1999, 14(10):2461-2463.
[cited by applicant]
Pronina et al., “Altered expression of the SEMA3B gene in epithelial tumors,” Cell Mol. Biol., Jun. 2009, 43(3):403-409.
[cited by applicant]
Ronco et al., “Membranous nephropathy,” Nat. Rev. Dis. Primers, Sep. 2021, 7(1):69.
[cited by applicant]
Sadeqzadeh et al., “Sleeping giants: emerging roles for the fat cadherins in health and disease,” Med. Res. Rev., Jan. 2014, 34(1):190-221.
[cited by applicant]
Sato et al., “Nephrotic syndrome in a bone marrow transplant recipient with chronic graft-versus-host disease,” Bone Marrow Transplant., Aug. 1995, 16(2):303-305.
[cited by applicant]
Sethi et al., “A proposal for standardized grading of chronic changes in native kidney biopsy specimens,” Kidney Int., Apr. 2017, 91(4):787-789.
[cited by applicant]
Sethi et al., “Abstract: PO1467: Hematopoietic Stem Cell Transplant Membranous Nephropathy Is Associated with Protocadherin FAT1,” Presented at the American Society of Nephrology Annual Meeting, Nov. 4, 2021, 2 pages.
[cited by applicant]
Sethi et al., “Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1,” J. Am. Soc. Nephrol., May 2022, 33(5):1033-1044.
[cited by applicant]
Sethi, “Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases,” Clin. Kidney J., Mar. 2021, 14(10):2166-2169.
[cited by applicant]
Sethi, “New ‘Antigens’ in Membranous Nephropathy,” J. Am. Soc. Nephrol., Feb. 2021, 32(2):268-278.
[cited by applicant]
Srinivasan et al., “Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation,” Br. J. Haematol., Oct. 2005, 131(1):74-79.
[cited by applicant]
Steen et al., “The ABC's (and XYZ's) of peptide sequencing,” Nat. Rev. Mol. Cell Biol., Sep. 2004, 5(9):699-711.
[cited by applicant]
Suzuki, “Protocadherins and diversity of the cadherin superfamily,” J. Cell Sci., Nov. 1996, 109(Pt. 11):2609-2611.
[cited by applicant]
Troxell et al., “Renal pathology associated with hematopoietic stem cell transplantation,” Adv. Anat. Pathol., Sep. 2014, 21(5):330-340.
[cited by applicant]
UniProt Accession No. Q14517, “FAT1_HUMAN,” Jul. 5, 2017, 9 pages.
[cited by applicant]
Wojtalwicz et al., “A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding, ” PLoS One, Mar. 2014, 9(3): e90461.
[cited by applicant]
Yaoita et al., “Role of Fat1 in cell-cell contact formation of podocytes in puromycin aminonucleoside nephrosis and neonatal kidney,” Kidney Int., Aug. 2005, 68(2):542-551.
[cited by applicant]
Yorioka et al., “Membranous nephropathy with chronic graft-versus-host disease in a bone marrow transplant recipient,” Nephron., Nov. 1998, 80(3):371-372.
[cited by applicant]
U.S. Appl. No. 18/843,878, filed Sep. 4, 2024, Sanjeev Sethi, Pending.
[cited by applicant]